HGS Calls For Confidence In Slow, Steady Ramp-Up For Benlysta

In the fourth quarter, the new SLE drug continued its slow sales growth – HGS said rheumatologists are still largely in trial mode, testing the drug in a few patients and gaining confidence in its benefits.